Mitsis Andreas, Myrianthefs Michael, Sokratous Stefanos, Karmioti Georgia, Kyriakou Michaela, Drakomathioulakis Michail, Tzikas Stergios, Kadoglou Nikolaos P E, Karagiannidis Efstratios, Nasoufidou Athina, Fragakis Nikolaos, Ziakas Antonios, Kassimis George
Cardiology Department, Nicosia General Hospital, State Health Services Organization, Nicosia 2029, Cyprus.
Third Department of Cardiology, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Biomedicines. 2024 Jul 26;12(8):1670. doi: 10.3390/biomedicines12081670.
Acute coronary syndrome (ACS) remains a major cause of morbidity and mortality worldwide, requiring ongoing efforts to identify novel therapeutic targets to improve patient outcomes. This manuscript reviews promising therapeutic targets for ACS identified through preclinical research, including novel antiplatelet agents, anti-inflammatory drugs, and agents targeting plaque stabilization. Preclinical studies have expounded these agents' efficacy and safety profiles in mitigating key pathophysiological processes underlying ACS, such as platelet activation, inflammation, and plaque instability. Furthermore, ongoing clinical trials are evaluating the efficacy and safety of these agents in ACS patients, with potential implications for optimizing ACS management. Challenges associated with translating preclinical findings into clinical practice, including patient heterogeneity and trial design considerations, are also discussed. Overall, the exploration of emerging therapeutic targets offers promising avenues for advancing ACS treatment strategies and improving patient outcomes.
急性冠状动脉综合征（ACS）仍然是全球发病和死亡的主要原因，需要持续努力寻找新的治疗靶点以改善患者预后。本文综述了通过临床前研究确定的有前景的ACS治疗靶点，包括新型抗血小板药物、抗炎药物和针对斑块稳定的药物。临床前研究阐述了这些药物在减轻ACS潜在关键病理生理过程（如血小板活化、炎症和斑块不稳定）方面的疗效和安全性。此外，正在进行的临床试验正在评估这些药物在ACS患者中的疗效和安全性，这可能对优化ACS管理具有重要意义。还讨论了将临床前研究结果转化为临床实践所面临的挑战，包括患者异质性和试验设计考虑因素。总体而言，探索新兴治疗靶点为推进ACS治疗策略和改善患者预后提供了有前景的途径。
